WASHINGTON, April 24, 2019 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that
Phaedra Chrousos has joined Vanda's Board of Directors, effective
April 23, 2019. Following Ms.
Chrousos' appointment, Vanda's Board of Directors is now
comprised of six directors.
"As we continue our drive towards growth through the pursuit of
innovation, it is an honor to welcome Phaedra to our Board," said
Mihael H. Polymeropoulos, M.D.,
President and Chief Executive Officer of Vanda. "Phaedra brings
acute and strategic insights that will help us deliver on our
corporate vision and more effectively leverage disruptive
technologies in support of our therapeutic initiatives. We are
confident her business acumen and consumer mindset will help Vanda
further accelerate our momentum in the industry."
Ms. Chrousos currently serves as the Chief Strategy Officer of
The Libra Group, where she leads a wide range of strategic
initiatives spanning technology transformation to operational
development. Headquartered in New
York and London, The Libra
Group is a diverse, international business group that is active in
35 countries and focused on six business areas: aviation, energy,
hospitality, real estate, shipping, and diversified investments.
Immediately prior to being appointed Chief Strategy Officer, Ms.
Chrousos served as the group's Chief Innovation Officer.
"Phaedra is a terrific addition to the Vanda Board. She brings
new skill sets, particularly in the areas of entrepreneurship and
consumer health care marketing, to the Board. Also, she helps
us further broaden the diversity of experiences and perspectives
among our Board members, which is critical for the Company's
growth," said H. Thomas Watkins,
Chairman of. Vanda's Board of Directors.
Previously, Ms. Chrousos served as a political appointee for the
Obama Administration in various roles, including as an Associate
Administrator for the General Services Administration. In this
capacity, Ms. Chrousos led the Office of Citizen Services and 18F,
a digital services team that implemented online service delivery
projects and open data initiatives at more than a dozen agencies,
including NIH, HHS and the VA. Prior to her departure from the
Administration, Ms. Chrousos helped found the Technology
Transformation Service, which serves as a foundation for the
government's ongoing digital transformation; she served as its
Founding Commissioner.
Prior to entering public service, Ms. Chrousos co-founded and
led two companies, including HealthLeap, a health tech company that
reimagined the way doctors and patients communicate. HealthLeap was
acquired by Vitals.com 10 months after its launch. She also has
several years of consulting experience with The Boston Consulting
Group and The World Bank.
Ms. Chrousos sits on several non-profit boards, including that
of a maternal mental health foundation, and was twice named one of
the Federal Government's '50 Women in Technology' by FedScoop and
one of Greece's '40 under 40' by
Fortune Magazine. Ms. Chrousos holds a B.A. from Georgetown University, an MSc from The London School of Economics and Political Science,
and an M.B.A. from Columbia Business
School.
About Vanda Pharmaceuticals Inc.
Vanda is a
global biopharmaceutical company focused on the development and
commercialization of innovative therapies to address high unmet
medical needs and improve the lives of patients. For more on Vanda
Pharmaceuticals Inc., please visit www.vandapharma.com.
Investor Contact:
Jim
Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contacts:
AJ Jones II
Burson Cohn & Wolfe (BCW)
1110 Vermont Avenue, NW, Suite 1200
Washington, D.C. 20005
202-530-0400
pr@vandapharma.com
Elizabeth Van Every
Burson Cohn & Wolfe (BCW)
230 Park Avenue South
New York, NY 10003
212-614-3881
pr@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-appoints-phaedra-chrousos-to-board-of-directors-300837651.html
SOURCE Vanda Pharmaceuticals Inc.